Furthermore, the analysis of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation, mutation analysis of the telomerase reverse transcriptase (TERT) promoter, and CDKN2A/B testing are essential for evaluation of glioma [1]. Here, MGMT is linked to central nervous system cancer.